171 related articles for article (PubMed ID: 34765926)
1. A single aromatic residue in sgp130Fc/olamkicept allows the discrimination between interleukin-6 and interleukin-11 trans-signaling.
Lokau J; Garbers Y; Grötzinger J; Garbers C
iScience; 2021 Nov; 24(11):103309. PubMed ID: 34765926
[TBL] [Abstract][Full Text] [Related]
2. Exclusive inhibition of IL-6 trans-signaling by soluble gp130
Berg AF; Ettich J; Weitz HT; Krusche M; Floss DM; Scheller J; Moll JM
Cytokine X; 2021 Dec; 3(4):100058. PubMed ID: 34927050
[TBL] [Abstract][Full Text] [Related]
3. Selective inhibition of IL-6 trans-signaling by a miniaturized, optimized chimeric soluble gp130 inhibits T
Heise D; Derrac Soria A; Hansen S; Dambietz C; Akbarzadeh M; Berg AF; Waetzig GH; Jones SA; Dvorsky R; Ahmadian MR; Scheller J; Moll JM
Sci Signal; 2021 Aug; 14(696):. PubMed ID: 34404751
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-6: from basic biology to selective blockade of pro-inflammatory activities.
Scheller J; Garbers C; Rose-John S
Semin Immunol; 2014 Feb; 26(1):2-12. PubMed ID: 24325804
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic Interleukin-6 Trans-signaling Inhibition by Olamkicept (sgp130Fc) in Patients With Active Inflammatory Bowel Disease.
Schreiber S; Aden K; Bernardes JP; Conrad C; Tran F; Höper H; Volk V; Mishra N; Blase JI; Nikolaus S; Bethge J; Kühbacher T; Röcken C; Chen M; Cottingham I; Petri N; Rasmussen BB; Lokau J; Lenk L; Garbers C; Feuerhake F; Rose-John S; Waetzig GH; Rosenstiel P
Gastroenterology; 2021 Jun; 160(7):2354-2366.e11. PubMed ID: 33667488
[TBL] [Abstract][Full Text] [Related]
6. Nonspecific Inhibition of IL6 Family Cytokine Signalling by Soluble gp130.
Widjaja AA; Cook SA
Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338642
[TBL] [Abstract][Full Text] [Related]
7. Selective blockade of interleukin-6 trans-signaling improves survival in a murine polymicrobial sepsis model.
Barkhausen T; Tschernig T; Rosenstiel P; van Griensven M; Vonberg RP; Dorsch M; Mueller-Heine A; Chalaris A; Scheller J; Rose-John S; Seegert D; Krettek C; Waetzig GH
Crit Care Med; 2011 Jun; 39(6):1407-13. PubMed ID: 21336117
[TBL] [Abstract][Full Text] [Related]
8. Targeting IL-6 trans-signalling: past, present and future prospects.
Rose-John S; Jenkins BJ; Garbers C; Moll JM; Scheller J
Nat Rev Immunol; 2023 Oct; 23(10):666-681. PubMed ID: 37069261
[TBL] [Abstract][Full Text] [Related]
9. Satralizumab might not be enough. Olamkicept (sgp130Fc) in Neuromyelitis Optica Spectrum Disorder.
Magro G
Mult Scler Relat Disord; 2022 Sep; 65():104037. PubMed ID: 35835028
[TBL] [Abstract][Full Text] [Related]
10. Effects of blockade of peripheral interleukin-6 trans-signaling on hippocampus-dependent and independent memory in mice.
Braun O; Dewitz C; Möller-Hackbarth K; Scheller J; Schiffelholz T; Baier PC; Rose-John S
J Interferon Cytokine Res; 2013 May; 33(5):254-60. PubMed ID: 23215755
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-11-driven gastric tumourigenesis is independent of trans-signalling.
Balic JJ; Garbers C; Rose-John S; Yu L; Jenkins BJ
Cytokine; 2017 Apr; 92():118-123. PubMed ID: 28160627
[TBL] [Abstract][Full Text] [Related]
12. Soluble gp130 prevents interleukin-6 and interleukin-11 cluster signaling but not intracellular autocrine responses.
Lamertz L; Rummel F; Polz R; Baran P; Hansen S; Waetzig GH; Moll JM; Floss DM; Scheller J
Sci Signal; 2018 Oct; 11(550):. PubMed ID: 30279168
[TBL] [Abstract][Full Text] [Related]
13. The role of interleukin-6 signaling in nervous tissue.
Rothaug M; Becker-Pauly C; Rose-John S
Biochim Biophys Acta; 2016 Jun; 1863(6 Pt A):1218-27. PubMed ID: 27016501
[TBL] [Abstract][Full Text] [Related]
14. Impact of interleukin-6 classic- and trans-signaling on liver damage and regeneration.
Drucker C; Gewiese J; Malchow S; Scheller J; Rose-John S
J Autoimmun; 2010 Feb; 34(1):29-37. PubMed ID: 19717281
[TBL] [Abstract][Full Text] [Related]
15. Structure-guided optimization of the interleukin-6 trans-signaling antagonist sgp130.
Tenhumberg S; Waetzig GH; Chalaris A; Rabe B; Seegert D; Scheller J; Rose-John S; Grötzinger J
J Biol Chem; 2008 Oct; 283(40):27200-7. PubMed ID: 18650419
[TBL] [Abstract][Full Text] [Related]
16. Proteolytic control of Interleukin-11 and Interleukin-6 biology.
Lokau J; Agthe M; Flynn CM; Garbers C
Biochim Biophys Acta Mol Cell Res; 2017 Nov; 1864(11 Pt B):2105-2117. PubMed ID: 28630024
[TBL] [Abstract][Full Text] [Related]
17. The soluble Interleukin 6 receptor: generation and role in inflammation and cancer.
Chalaris A; Garbers C; Rabe B; Rose-John S; Scheller J
Eur J Cell Biol; 2011; 90(6-7):484-94. PubMed ID: 21145125
[TBL] [Abstract][Full Text] [Related]
18. The balance of interleukin (IL)-6, IL-6·soluble IL-6 receptor (sIL-6R), and IL-6·sIL-6R·sgp130 complexes allows simultaneous classic and trans-signaling.
Baran P; Hansen S; Waetzig GH; Akbarzadeh M; Lamertz L; Huber HJ; Ahmadian MR; Moll JM; Scheller J
J Biol Chem; 2018 May; 293(18):6762-6775. PubMed ID: 29559558
[TBL] [Abstract][Full Text] [Related]
19. Case Report: Arterial Wall Inflammation in Atherosclerotic Cardiovascular Disease is Reduced by Olamkicept (sgp130Fc).
Schulte DM; Waetzig GH; Schuett H; Marx M; Schulte B; Garbers C; Lokau J; Vlacil AK; Schulz J; Seoudy AK; Schieffer B; Rosenstiel P; Seeger M; Laudes M; Rose-John S; Lützen U; Grote K; Schreiber S
Front Pharmacol; 2022; 13():758233. PubMed ID: 35754497
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-6 trans-signaling contributes to chronic hypoxia-induced pulmonary hypertension.
Maston LD; Jones DT; Giermakowska W; Resta TC; Ramiro-Diaz J; Howard TA; Jernigan NL; Herbert L; Maurice AA; Gonzalez Bosc LV
Pulm Circ; 2018; 8(3):2045894018780734. PubMed ID: 29767573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
